MARKET

AGRX

AGRX

Agile
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.880
+0.080
+2.86%
After Hours: 2.900 +0.02 +0.69% 19:11 09/25 EDT
OPEN
2.820
PREV CLOSE
2.800
HIGH
2.890
LOW
2.780
VOLUME
977.87K
TURNOVER
--
52 WEEK HIGH
4.765
52 WEEK LOW
0.3500
MARKET CAP
251.42M
P/E (TTM)
-7.1041
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 23, 2020
GlobeNewswire · 3d ago
AGRX, AVDL among pre-market gainers
NTN Buzztime (NTN) +20% on offloading entertainment and advertising assets.Leap Therapeutics (LPTX) +7% on initiating DKN-01+tislelizumab combination mid-stage study in gastric cancer.Agile Therapeutics (AGRX) +7%.Avadel Pharmaceuticals (AVDL) +5%.Aemetis (AMTX) +5%.PolyMet Mining (PLM) +5%.
Seekingalpha · 4d ago
Stocks To Watch: All Eyes On Tesla Battery Day
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). Tesla (TSLA) will take top billing this week with its highly-anticipated Battery Day event having the potential to charge up animal spirits in the market again. The earnings calendar features high-flyers Nike (NKE) and Costco (COST), while Apple (AAPL) will
Seekingalpha · 6d ago
Agenus, Achieve Life Sciences leads gainers, Satsuma Pharmaceuticals, Precipio among losers
Gainers:  Agenus (AGEN) +13%, Achieve Life Sciences (ACHV) +7%, Agile Therapeutics (AGRX) +7%, Akouos (AKUS) +7%, Adial Pharmaceuticals (ADIL) +6%.Losers: Satsuma Pharmaceuticals (STSA) -75%, Precipio (PRPO) -22%, Sutro Biopharma (STRO) -18%, Athenex (ATNX) -16%, Spero Therapeutics (SPRO) -15%.
Seekingalpha · 09/10 15:10
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment
GlobeNewswire · 09/09 12:00
Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020
Company to Present Twirla® Commercial Plan Webcast Scheduled from 11:00 am – 1:00 pm EDTPRINCETON, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will host a virtual Investor/Analyst Day on Monday, September
GlobeNewswire · 09/08 13:00
Agile Therapeutics Launches Im So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control
Agile Therapeutics’ I’m So Done Campaign I’m So Done Agile Therapeutics’ I’m So Done Campaign I’m So DoneVisit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options * I’m So Done is a national unbranded campaign intended to enhance the birth control conversation
GlobeNewswire · 09/02 14:00
Agile Therapeutics: Taking A Victory Lap While We Wait For Twirla's Commercial Launch
My original Agile Therapeutics investment thesis and plan have worked out exactly how I planned them. Now, I am looking to take a victory lap ahead of Twirla's commercial launch.
Seeking Alpha - Article · 09/01 00:28
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGRX. Analyze the recent business situations of Agile through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGRX stock price target is 8.50 with a high estimate of 12.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 47.57M
% Owned: 54.50%
Shares Outstanding: 87.30M
TypeInstitutionsShares
Increased
28
8.15M
New
51
-489.73K
Decreased
9
2.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Director
Alfred Altomari
Chief Financial Officer/Senior Vice President
Dennis Reilly
Senior Vice President/General Counsel/Secretary
Geoffrey Gilmore
Senior Vice President
Robert Conway
Other
Paul Korner
Lead Director/Independent Director
Seth Fischer
Director
Sandra Carson
Independent Director
Sharon Barbari
Independent Director
John Hubbard
Independent Director
Ajit Shetty
Independent Director
James Tursi
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AGRX
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Agile Therapeutics Inc stock information, including NASDAQ:AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.